Document is current
Any future updates will be listed below
-
Authors
Rutherford, Claudia https://orcid.org/0000-0002-4637-4572
Tait, Margaret-Ann
Costa, Daniel S. J.
King, Madeleine T.
Smith, David P.
Sengupta, Shomik
Ischia, Joseph
Mitterdorfer, Andrew
Hayne, Dickon
Watson, Roger
Anderson, Paul
Frydenberg, Mark
Gilling, Peter
Buchan, Nicholas
Green, Euan
Clarke, Noel
Boorjian, Stephen A.
Konety, Badrinath
Holzbeierlein, Jeffrey M.
Black, Peter C.
Chalasani, Venu
Henseler, Jörg
Patel, Manish I.
,
-
Funding
Funding for this research was provided by:
Cancer Council NSW and Cancer Australia (1103036)
- License Information
-
More Information
Article History
Received: 9 September 2024
Accepted: 9 March 2025
First Online: 27 March 2025
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Northern Sydney Local Health District Human Research Ethics Committee on 26 October 2016 (HREC/16/HAWKE/329). Written informed consent was obtained from all individual participants included in the study. Consent included publication of results from this study in the form of anonymised survey data.
: Not applicable.
: ClinicalTrials.gov NCT03091764, 27 March 2017. .
: The co-authors have disclosed the following as financial interests, relationships, and affiliations relevant to the subject matter discussed in the manuscript: SAB is a consultant for Ferring, FerGene, Artara, and Prokarium. SS is an unpaid board director of ANZUP trials group. Has been an adviser/speaker for Mundipharma, Ipsen, Abbvie and MSD (with honoraria donated directly into departmental research funds) and a paid adviser to Janssen. NB is an unpaid board director of ANZUP trials group. BK is a consultant for Ferring Pharmaceuticals Inc and Investigator clinical trial, Pacific Edge. MP is an advisor/speaker for Jannsen, MSD, Mundipharma, Astra Zenaca. The remaining authors declare that they have no competing interests.
